25 Innovators Share Why TEDCO’s 25 Years Have Made Such a Difference in Maryland

Published on :

In honor of the 25 years that TEDCO has been supporting the dreams of entrepreneurs across Maryland and building the foundation of our innovation economy, we asked 25 people that TEDCO has impacted over the years what the organization has meant to them.  

Vector BioMed Launches in Maryland with Gene Therapy Industry Veteran at Helm to Address the Vector Supply Bottleneck with End-to-End Solutions Platform

Published on :

Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
NEWS PROVIDED BY
Vector BioMed
Jan 31, 2023, 07:30 ET
SHARE THIS ARTICLE
First Round Funding Led by Viking Global Investors and Casdin Capital
Boro Dropulić, Ph.D., MBA, named Chief Executive Officer of Vector BioMed
GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ — Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
In contrast to traditional contract development and manufacturing organizations (CDMOs), Vector BioMed is a solution provider that will provide partners with the capabilities to take their lentiviral vector-based medicinal concepts into the clinic and accelerate their path to commercialization. Vector BioMed will help address the industry’s current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services.
In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has…

Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

Published on :

Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
– Reports Promising Early Data from Lead Clinical Program, JK07, for the Treatment of Heart Failure with Reduced Ejection Fraction –
– Initiates Enrollment in Second Cohort of JK07 Phase 1 Dose Escalation Study –
March 07, 2022 07:00 AM Eastern Standard Time
GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. The investment, which was completed in the fourth quarter of 2021, will be used to advance the current pipeline, including continuation of an ongoing Phase 1b clinical trial and initiation of two additional Phase 1b clinical trials in 2022, and to further expand the pipeline through R&D.
“SalubrisBio is poised for a transformational year and I’m excited about the remarkable opportunities that lie ahead for us”
Tweet this
“SalubrisBio is poised for a transformational year and I’m excited about the remarkable opportunities that lie ahead for us,” said Sam Murphy, Chief Executive Officer of SalubrisBio. “We are focused on advancing our programs and securing additional funding…

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire

Published on :

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–Contraline, Inc., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing. The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies. Additional investors in Contraline include: Rhia Ventures, ShangBay Capital, Founders Fund, Metaplanet Holdings, Graphene Ventures, Smith Ventures, Jaffray Woodriff, and Jason Calacanis.
“I believe that Contraline’s product ADAM could be a game changer for men who want more control over their fertility as well as couples who struggle with their reliance on female contraception.”
Tweet this
This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men. The ADAM hydrogel is injected into the vas deferens through a quick and minimally invasive outpatient procedure, where it’s designed to block the flow of sperm. Contraline has received ethics approval from the Human Research Ethics Committee based in Melbourne, Australia to conduct the study. The clinical trial will be conducted by renown urologists at two hospitals in Melbourne. This trial on ADAM is believed…

D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases

Published on :

GAITHERSBURG, Md.–(BUSINESS WIRE)–D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc., Theraly Fibrosis Inc., P4Microbiome and Valted Seq, today announced that it has completed a $51 million Series C round of financing led by Praxis Capital Partners, a private equity firm that focuses on growth acquisitions and investments in Asia; other investors included DS Asset Management, Kudos Ventures and Korea Investment & Securities. The new round of financing builds upon the $137.1 million the company secured in Series B financing in August 2019. The company is planning an initial public offering in Korea in 2022.
“We have been very impressed with the founders and team leaders of D&D and their subsidiaries, as well as their world-class drug development capabilities and ongoing clinical trials”
Tweet this
“We are grateful for the ongoing support and confidence of our investors and excited to have had Praxis Capital lead this Series C financing,” said Yoo-Seok Hong, Chief Executive Officer of D&D Pharmatech. “We look forward to the ongoing advancement of our clinical candidates in a diverse range of diseases with significant unmet need and the expansion of our…